Background and Objective: Mycoplasmal pneumonia (MP) can lead to inflammation,
multiple system immune damage, and mixed infection in children. The pathogenesis is still
unclear. Shuang-Huang-Lian (SHL) oral liquid can treat acute upper respiratory tract infection,
acute bronchitis and light pneumonia. However, our current understanding of the molecular
mechanisms supporting its clinical application still lags behind due to the lack of researches. It is
difficult to understand the overall sensitization mechanism of SHL oral liquid. The purpose is to
explain the mechanism of action of drugs in this study, which is useful to ensure the safety of
medication for children.
Methods: The therapeutic mechanism of SHL oral liquid was investigated by a system
pharmacology approach integrating drug-likeness evaluation, oral bioavailability prediction,
ADMET, protein-protein interaction worknet, Gene Ontology enrichment analysis, Kyoto
Encyclopedia of Genes and Genomes database pathway performance, C-T-P network construction
and molecular docking.
Results: A total of 18 active ingredients contained in SHL oral liquid and 53 major proteins were
screened out as effective players in the treatment of M. pneumoniae disease through some related
pathways and molecular docking. The majority of targets, hubs and pathways were highly related
to anti-mycoplasma therapy, immunity and inflammation process.
Conclusion: This study shows that the anti-bacterial effect of SHL oral liquid has multicomponent,
multi-target and multi-pathway phenomena. The proposed approach may provide a
feasible tool to clarify the mechanism of traditional Chinese medicines and further develop their